Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D3RS
|
|||
| Drug Name |
Biaryl compound 1
|
|||
| Synonyms |
PMID30107136-Compound-Example10
Click to Show/Hide
|
|||
| Drug Type |
Small molecule immunotherapy
|
|||
| Indication | Hepatitis [ICD-11: DB97.Z] | Patented | [1] | |
| Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 42] | Patented | [1] | ||
| Infectious disease [ICD-11: 1A00-CA43.1; ICD-10: A00-B99; ICD-9: 001-139] | Patented | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Patented | [1] | ||
| Company |
BRISTOL-MYERS SQUIBB COMPANY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C49H43Cl2N5O8
|
|||
| Canonical SMILES |
CC1=C(C=CC=C1C2=CC=CC(=C2C)COC3=C(C=C(C(=C3)OCC4=CC(=CN=C4)C#N)C(=O)C)Cl)COC5=C(C=C(C(=C5)OCC6=CC(=CN=C6)C#N)CNC(C)(CO)C(=O)O)Cl
|
|||
| InChI |
1S/C49H43Cl2N5O8/c1-29-36(26-63-46-15-44(61-24-34-11-32(17-52)19-54-21-34)38(13-42(46)50)23-56-49(4,28-57)48(59)60)7-5-9-39(29)40-10-6-8-37(30(40)2)27-64-47-16-45(41(31(3)58)14-43(47)51)62-25-35-12-33(18-53)20-55-22-35/h5-16,19-22,56-57H,23-28H2,1-4H3,(H,59,60)
|
|||
| InChIKey |
LBEJCLGFPBJTDE-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CD80-PD-L1 interaction (CD80/PD-L1 PPI) | Target Info | Inhibitor | [1] |
| PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | CD80-PD-L1 interaction (CD80/PD-L1 PPI) | Target's Patent Info | [1] | |
| PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) | Target's Patent Info | [1] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.